KALA BIO (KALA) Competitors

KALA BIO (NASDAQ:KALA) and Onconova Therapeutics (NASDAQ:ONTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Does the media favor KALA or ONTX?

In the previous week, KALA BIO had 2 more articles in the media than Onconova Therapeutics. MarketBeat recorded 3 mentions for KALA BIO and 1 mentions for Onconova Therapeutics. KALA BIO's average media sentiment score of 0.15 beat Onconova Therapeutics' score of 0.00 indicating that KALA BIO is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
KALA BIO	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Onconova Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has preferable valuation & earnings, KALA or ONTX?

Onconova Therapeutics has lower revenue, but higher earnings than KALA BIO. KALA BIO is trading at a lower price-to-earnings ratio than Onconova Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	$3.89M	4.89	-$42.20M	-$17.94	-0.38
Onconova Therapeutics	$230K	0.00	-$18.96M	-$0.91	N/A

Does the MarketBeat Community prefer KALA or ONTX?

Onconova Therapeutics received 85 more outperform votes than KALA BIO when rated by MarketBeat users. However, 66.59% of users gave KALA BIO an outperform vote while only 59.69% of users gave Onconova Therapeutics an outperform vote.

Company	Underperform	Outperform
KALA BIO	Outperform Votes 297 66.59%	Underperform Votes 149 33.41%
Onconova Therapeutics	Outperform Votes 382 59.69%	Underperform Votes 258 40.31%

Do institutionals and insiders hold more shares of KALA or ONTX?

24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 8.0% of Onconova Therapeutics shares are owned by institutional investors. 13.4% of KALA BIO shares are owned by company insiders. Comparatively, 3.3% of Onconova Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Is KALA or ONTX more profitable?

KALA BIO has a net margin of 0.00% compared to Onconova Therapeutics' net margin of -8,930.97%. Onconova Therapeutics' return on equity of -95.43% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-281.02%	-65.57%
Onconova Therapeutics	-8,930.97%	-95.43%	-61.19%

Which has more risk and volatility, KALA or ONTX?

KALA BIO has a beta of -1.85, indicating that its stock price is 285% less volatile than the S&P 500. Comparatively, Onconova Therapeutics has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500.

Do analysts recommend KALA or ONTX?

KALA BIO currently has a consensus target price of $18.00, suggesting a potential upside of 166.67%. Onconova Therapeutics has a consensus target price of $11.00, suggesting a potential upside of ∞. Given Onconova Therapeutics' higher probable upside, analysts clearly believe Onconova Therapeutics is more favorable than KALA BIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Onconova Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

KALA BIO beats Onconova Therapeutics on 9 of the 16 factors compared between the two stocks.